Global Point of Care
Global Point of Care
Abbott Point of Care (APOC) partners with physicians and researchers globally to advance scientific knowledge and evidence of our products in various clinical settings to help accelerate patient care. Below is a compilation of peer reviewed journal articles and editorials demonstrating the clinical, analytical, operational, and economic value of APOC products.
Click the blue titles below to launch the publication.
Title |
Source |
Sample size |
Summary |
---|---|---|---|
ACADEMIC EMERGENCY MEDICINE. Bazarian et al 2021; 00:1–10 |
2011 |
Objectives: To determine the accuracy of a new, rapid blood test combining measurements of both glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) for predicting acute traumatic intracranial injury (TII) on head CT scan after mild traumatic brain injury (mTBI). Findings: i-STAT TBI Plasma test had high sensitivity for prediction of acute TII, comparable to lab-based platforms. The speed, portability, and high accuracy of this test may facilitate clinical adoption of brain biomarker testing as an aid to head CT decision making in EDs. |
|
ADVANCED EMERGENCY NURSING JOURNAL, |
201 |
Objectives: Impact of point of care (POC) troponin testing on turnaround times, door-to-troponin result time, ED Length of Stay (LOS) in patients with chest pain, and staff satisfaction with POC testing was evaluated. |
|
THE JOURNAL OF EMERGENCY MEDICINE, |
104 |
Objectives: Value of early point of care testing (POCT) at the time of patient triage prior to physician evaluation in the Emergency Department (ED) was evaluated at a tertiary care medical center. POCT was available for basic metabolic panel, troponin I, lactate, International Normalized Ratio (INR), or urine pregnancy test. Findings: ED care times reduced by approximately 1 hour with early POCT at triage compared with traditional core laboratory testing. Approximately 6% of the patients were immediately transferred to critical care areas to be seen by an ED physician. Slightly more than half of the treating physicians felt that early POCT at the time of initial assessment improved patient care, by changing the focus of their evaluation or leading to earlier treatment or disposition. In this study, although ED care times were reduced, total ED length of stay was not reduced. |
|
Does Rapid Assessment Shorten the Amount of Time Patients Spend in the Emergency Department? |
BRITISH JOURNAL OF HOSPITAL MEDICINE, *Dr. Jarvis no longer works as a consultant at Calderdale Royal Hospital and he is currently employed by Abbott Laboratories. |
4,622 |
Objectives: Traditional patient triage (nurse-led triage model with blood samples analyzed in a centralized hospital laboratory) was compared with a consultant-supported rapid assessment model (EDIT model) with blood samples analyzed using the i-STAT System as the point of care (POC) solution in the Emergency Department (ED) of a district general hospital. |
POINT OF CARE, |
41 |
Objectives: Economic value of point of care testing (POCT) was assessed in a Swedish Emergency Department. Direct cost of POCT vs. central laboratory and indirect costs such as reduction in waiting time was analyzed. i-STAT CHEM8+, CG4+, and cTnI cartridges were used. |
|
ADVANCED EMERGENCY NURSING JOURNAL, |
201 |
Objectives: Impact of point of care (POC) troponin testing on turnaround times, door-to-troponin result time, ED Length of Stay (LOS) in patients with chest pain, and staff satisfaction with POC testing was evaluated. |
Click the blue titles below to launch the publication.
Title |
Source |
Sample size |
Summary |
---|---|---|---|
Clinical Evaluation of Measuring the ACT During Elective Cardiac Surgery with Two Different Devices |
JOURNAL OF EXTRA CORPOREAL TECHNOLOGY, |
402 |
Objectives: Multi-site study across UK, South Africa and Switzerland evaluated Activated Clotting Time (ACT) measurements with two devices, i-STAT and Hemochron Jr. Patients undergoing elective cardiac surgery on cardiopulmonary bypass were included. Findings: i-STAT ACT test demonstrated good correlation with Hemochron Jr with i-STAT reading slightly higher than Hemochron Jr. Additionally, i-STAT consistently demonstrated lower within-subject coefficient of variation (WSCV) compared to Hemochron Jr, making it more reliable for clinical decision making. Authors commented that the better reliability of the i-STAT may be due to the difference in ACT methodology. |
A Two Site Comparison of Two Point of Care Activated Clotting Time Systems |
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, |
177 |
Objectives: i-STAT Activated Clotting Time (ACT) and Hemochron Signature Elite ACT values were compared using split samples from patients undergoing invasive surgery at two cardiothoracic institutes in the Netherlands and Germany. Findings: i-STAT ACT values demonstrated better reproducibility (mean difference - 4.3% vs. 9.1%) and correlation compared to the Hemochron. In the therapeutic area (>250 s), Hemochron duplicate measurements became less precise. There are different possible explanations for the correlation results between the Hemochron and the i-STAT. The i-STAT is less susceptible to changes in fibrinogen levels, temperature, hematocrit and hemodilution compared to the Hemochron. These findings reflects precision and not accuracy. Since there is no true ACT value, clinicians rely on the precision (reproducibility) of tests. |
Click the blue titles below to launch the publication.
Title |
Source |
Sample size |
Summary |
---|---|---|---|
CLINICO ECONOMICS AND OUTCOME RESEARCH, |
200 |
Objectives: Economic value of i-STAT point-of-care (POCT) testing at six primary health care facilities in rural and remote communities in Australia, where hospital and laboratory facilities are unavailable were evaluated. Economic evaluation was conducted using data from patients presenting with three common acute conditions (chest pain, chronic renal failure due to missed dialysis session(s), and acute diarrhea). The number of unnecessary medical evacuations prevented with the use of POCT as an aid in decision-making for acutely ill patients was used as a basis of calculating cost savings per patient and Northern Territory (NT) wide. |
The results shown here are specific to one health care facility and may differ from those achieved by other institutions.
A Leader In Rapid Point-of-care Diagnostics.
©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.